The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6354
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study ; volume:12 ; number:2 ; day:2 ; month:3 ; year:2010 ; pages:1-12 ; date:4.2010
Arthritis Research & Therapy ; 12, Heft 2 (2.3.2010), 1-12, 4.2010
- Creator
-
Wolfe, Frederick
- Contributor
-
Michaud, Kaleb
SpringerLink (Online service)
- DOI
-
10.1186/ar2944
- URN
-
urn:nbn:de:1111-2016050315161
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:52 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Wolfe, Frederick
- Michaud, Kaleb
- SpringerLink (Online service)
Other Objects (12)
Biologic monotherapy in the biologic naïve patient with rheumatoid arthritis (RA): results from an observational study
Administration costs of intravenous biologic drugs for rheumatoid arthritis
Do biologic therapies reduce aortic inflammation in rheumatoid arthritis patients?
Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry
Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics
Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?
The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs
Pelvic peritonitis during biologic therapy for rheumatoid arthritis: a case report and review of the literature
Association between autophagy and inflammation in patients with rheumatoid arthritis receiving biologic therapy
Biologic monotherapy in the biologic naïve patient with rheumatoid arthritis (RA): results from an observational study
Administration costs of intravenous biologic drugs for rheumatoid arthritis
Do biologic therapies reduce aortic inflammation in rheumatoid arthritis patients?
Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry
Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics
Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?
The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs
Pelvic peritonitis during biologic therapy for rheumatoid arthritis: a case report and review of the literature
Association between autophagy and inflammation in patients with rheumatoid arthritis receiving biologic therapy
Biologic monotherapy in the biologic naïve patient with rheumatoid arthritis (RA): results from an observational study
Administration costs of intravenous biologic drugs for rheumatoid arthritis
Do biologic therapies reduce aortic inflammation in rheumatoid arthritis patients?
Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry
Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics
Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?
The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs
Pelvic peritonitis during biologic therapy for rheumatoid arthritis: a case report and review of the literature